Aristides Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Aristides Capital’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-106,333	Closed	-$314K	–	261
2024 Q2	$314K	Hold	106,333	–	–	0.09%	145
2024 Q1	$295K	Hold	106,333	–	–	0.11%	140
2023 Q4	$302K	Hold	106,333	–	–	0.11%	123
2023 Q3	$274K	Buy	+106,333	New	+$342K	0.12%	114

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aristides Capital's DMAC Position: Q3 2024 in Review

Aristides Capital sold out of DiaMedica Therapeutics (DMAC) in Q3 2024, closing a stake of 106,333 shares — an estimated $314K sold.

Aristides Capital first reported a position in DMAC in Q3 2023 and held it in 4 quarters. The position peaked at $314K in Q2 2024. 40 funds tracked by Wall St. Rank hold DMAC as of Q3 2024.

Aristides Capital reported no remaining DiaMedica Therapeutics position as of Q3 2024 after selling out during the quarter.
Aristides Capital sold 106,333 DiaMedica Therapeutics shares in Q3 2024, an estimated $314K.
Aristides Capital first reported a position in DiaMedica Therapeutics in Q3 2023 and held it in 4 quarters.
Aristides Capital's DiaMedica Therapeutics position peaked at $314K in Q2 2024.
40 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2024.

Based on Aristides Capital's 13F filing for Q3 2024, filed 14 Nov 2024.